These results imply that Thrap3 LKO restored mitochondrial dysfunction, prevented the vicious cycle leading to ROS overproduction and hepatic steatosis, and finally ameliorated the NAFLD phenotype. This evidence concerns the gene THRAP3 and fatty liver disease.